Lyell Immunopharma’s LYL314 shows strong response in Phase 1/2 lymphoma trial

Lyell Immunopharma (LYEL) announced positive new clinical data from the multi-center Phase 1/2 trial of LYL314, including data from patients with large B-cell lymphoma, or LBCL, treated in the third- or later-line setting. LYL314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor T-cell product candidate with Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA, in development for patients with relapsed and/or refractory LBCL. In patients treated in the 3L+ setting, LYL314 continued to demonstrate robust clinical responses, with an 88% overall response rate and a 72% complete response rate. Of the 3L+ patients who achieved a complete response, 71% remained in complete response at greater than or equal to 6 months. The single-arm pivotal PiNACLE trial is underway.